Working... Menu

Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03149939
Recruitment Status : Completed
First Posted : May 11, 2017
Last Update Posted : May 11, 2017
New Jeddah Clinic Hospital
Information provided by (Responsible Party):
Mahmoud Hamada imam, Benha University

Brief Summary:
Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Condition or disease Intervention/treatment Phase
Hyperuricemia Hemodialysis Complication Drug: Febuxostat 40 milligramsTablet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : April 1, 2017
Actual Study Completion Date : May 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
Drug Information available for: Febuxostat

Intervention Details:
  • Drug: Febuxostat 40 milligramsTablet
    Febuxostat 40 milligramsTablet every other day for 3 months

Primary Outcome Measures :
  1. Change in serum uric acid [ Time Frame: at three months of Febuxostat 40 milligrams Tablet therapy ]
    Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age above 18 years
  • Hemodialysis patient
  • Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion Criteria:

  • Patient currently and/or recently received drugs for hyperuricemia within the last three months
  • Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Layout table for additonal information
Responsible Party: Mahmoud Hamada imam, MD. - Lecturer at Internal Medicine Department- Faculty of Medicine, Benha University Identifier: NCT03149939     History of Changes
Other Study ID Numbers: BN-0316
First Posted: May 11, 2017    Key Record Dates
Last Update Posted: May 11, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Gout Suppressants
Antirheumatic Agents